about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

A uni­corn built on lies? Founders of Sanofi part­ner may face 20 years in prison for al­leged­ly prof­it­ing from stolen ...

4 years ago
People

Af­ter sell­ing its spin­out to Bay­er in a $875M-plus deal, NeRRe Ther­a­peu­tics grabs $28M for some 'un­fin­ished busi­ness'

4 years ago
Financing

Start­up boast­ing 'gob­stop­per-style' vac­cine de­liv­ery draws big part­ner­ships — and back­ing from Ad­ju­vant Cap­i­tal

4 years ago
Financing
Startups

If you thought the FDA’s ap­proval of Aduhelm for Alzheimer’s was con­tro­ver­sial, you should hear the ex­pert­s' ...

4 years ago
Pharma

Eu­ro­pean Com­mis­sion clears As­traZeneca's $39B bid for Alex­ion and a fu­ture in rare dis­eases. Now there's just a fi­nal ...

4 years ago
Deals

Watch out, Pfiz­er and Mod­er­na; An­ti-ag­ing break­through in mice?; Neu­ro for the new GSK; and more

4 years ago
Weekly

Hal Bar­ron's chase for ge­net­ic clues leads Glax­o­SmithK­line back to neu­ro — and makes new biotech part­ner $700M ...

4 years ago
Deals

Bask­ing in lime­light of a CRISPR break­through, In­tel­lia bags $600M cash raise as shares soar to all-time high

4 years ago
Financing

Ab­b­Vie says Rin­voq shines again as main­te­nance ther­a­py for ul­cer­a­tive col­i­tis — but safe­ty con­cerns still loom over ...

4 years ago
R&D
Pharma

Io­vance's TIL ther­a­py makes ear­ly head­way in lung can­cer; An­tios and Ar­bu­tus join hands on HBV com­bo treat­ment

4 years ago
News Briefing

Alzheimer's gold rush in­spires $565M deal be­tween Chi­nese phar­ma pow­er­house and lit­tle Ger­man biotech

4 years ago
Deals

Covid-19 roundup: Mod­er­na vac­cine kicks up an­ti­bod­ies against Delta vari­ant; UK study val­i­dates mix-and-match ...

4 years ago
Coronavirus

Eras­ing can­cer, re­viv­ing on­colyt­ic virus, treat­ing a rare neu­ro­mus­cu­lar con­di­tion: Here's what you need to know about ...

4 years ago
Financing

Sanofi, As­traZeneca mark big leap to­ward fil­ing of RSV drug in 2022, with safe­ty da­ta in hand to chal­lenge Synagis

4 years ago
R&D

Are 'plat­form plays' here to stay?; The Aduhelm saga con­tin­ues to un­fold; A new GSK?; and more

4 years ago
Weekly

What con­tro­ver­sy? Eli Lil­ly plots Alzheimer's BLA fil­ing lat­er this year as FDA taps more an­ti-amy­loid drugs as ...

4 years ago
FDA+

Mul­ti­va­lent mR­NA vac­cines, I/O 3.0, long-act­ing HIV drugs: The $46B game is on for the new Glax­o­SmithK­line

4 years ago
Pharma

Chas­ing 'Holy Grail' STAT3 tar­get, Hous­ton start­up re­fu­els with $74M to ze­ro in on liv­er can­cer

4 years ago
Financing

Yescar­ta goes to Chi­na as Fo­s­un Kite nabs his­toric first CAR-T OK

4 years ago
China
Cell/Gene Tx

Roche's Alzheimer's drug spurred bio­mark­er changes but no cog­ni­tive im­pact — pa­per; vTv out-li­cens­es for­mer lead ...

4 years ago
News Briefing

Top an­a­lyst chimes in on bub­bling de­bate about Glax­o­SmithK­line's fu­ture with a clear mes­sage: Let your £40B vac­cines ...

4 years ago
Pharma

They went from dai­ly to once every two months. But how much longer act­ing can HIV meds be? Vi­iV en­lists Halozyme's ...

4 years ago
Deals

Al­lo­gene, Over­land woo an ex­pe­ri­enced hand from WuXi to steer their al­lo­gene­ic CAR-T JV

4 years ago
People
China

Ac­tivist in­vestor El­liott in talks with oth­er Glax­o­SmithK­line in­vestors about re­plac­ing Em­ma Walm­s­ley, spin­ning off ...

4 years ago
People
Pharma
First page Previous page 48495051525354 Next page Last page
A service from the Financial Times